Edgar Filing: AMICUS THERAPEUTICS INC

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â NEFF P SHERRILL

2. Date of Event Requiring Statement (Month/Day/Year)
05/30/2007

3. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [FOLD]

(Last)

(First)

(Middle)

C/O QUAKER BIOVENTURES,Â 2929 ARCH STREET, CIRA CENTRE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

PHILADELPHIA,Â PAÂ 19104

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series C Convertible Preferred Stock	08/16/2005	Â ⁽³⁾	Common Stock	396,825 ⁽³⁾	$ 0 ⁽³⁾	I	Quaker BioVentures, L.P. ⁽¹⁾
Series C Convertible Preferred Stock	08/16/2005	Â ⁽³⁾	Common Stock	132,275 ⁽³⁾	$ 0 ⁽³⁾	I	Garden State Life Sciences Venture Fund, L.P. ⁽²⁾
Series C Convertible Preferred Stock	04/17/2006	Â ⁽³⁾	Common Stock	396,825 ⁽³⁾	$ 0 ⁽³⁾	I	Quaker BioVentures, L.P. ⁽¹⁾
Series C Convertible Preferred Stock	04/17/2006	Â ⁽³⁾	Common Stock	132,275 ⁽³⁾	$ 0 ⁽³⁾	I	Garden State Life Sciences Venture Fund, L.P. ⁽²⁾
Series D Convertible Preferred Stock	09/13/2006	Â ⁽³⁾	Common Stock	135,586 ⁽³⁾	$ 0 ⁽³⁾	I	Quaker BioVentures, L.P. ⁽¹⁾
Series D Convertible Preferred Stock	09/13/2006	Â ⁽³⁾	Common Stock	45,195 ⁽³⁾	$ 0 ⁽³⁾	I	Garden State Life Sciences Venture Fund, L.P. ⁽²⁾
Series D Convertible Preferred Stock	03/09/2007	Â ⁽³⁾	Common Stock	135,586 ⁽³⁾	$ 0 ⁽³⁾	I	Quaker BioVentures, L.P. ⁽¹⁾
Series D Convertible Preferred Stock	03/09/2007	Â ⁽³⁾	Common Stock	45,195 ⁽³⁾	$ 0 ⁽³⁾	I	Garden State Life Sciences Venture Fund, L.P. ⁽²⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
NEFF P SHERRILL C/O QUAKER BIOVENTURES 2929 ARCH STREET, CIRA CENTRE PHILADELPHIA,Â PAÂ 19104	Â X	Â X	Â	Â

Signatures

/s/ Sherrill Neff		05/30/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reporting person is a member of Quaker BioVentures Capital, L.P., which is the general partner of Quaker BioVentures, L.P. Voting and investment power over these shares is exercised by Quaker BioVentures Capital, L.P. in its role as general partner and investment advisor of Quaker BioVentures, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.
(2)	The reporting person is a member of Quaker BioVentures Capital, L.P., which is the general partner of Garden State Life Sciences Venture Fund, L.P. Voting and investment power over these shares is exercised by Quaker BioVentures Capital, L.P. in its role as general partner and investment advisor of Garden State Life Sciences Venture Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or any other purpose.
(3)	Each share is convertible and will automatically convert on a 1-for-1 basis into the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock pursuant to an effecive registration statement filed with the U.S. Securities and Exchange Commission. These shares have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.